Japanese Journal of Transplantation and Cellular Therapy
Online ISSN : 2436-455X
Current issue
Displaying 1-7 of 7 articles from this issue
Review
  • Shinsuke Takagi
    2025 Volume 14 Issue 1 Pages 1-5
    Published: 2025
    Released on J-STAGE: January 15, 2025
    JOURNAL FREE ACCESS

     Sinusoidal obstruction syndrome (SOS) is one of the major complications after hematopoietic cell transplantation and is fatal in severe cases. The modified Seattle and Baltimore criteria have been used for many years. New diagnostic criteria were proposed by the European Society for Blood and Marrow Transplantation (EBMT, European Society for Blood and Marrow Transplantation) in 2016 and subsequently, its revised version was published in 2023. This article discusses the current status and future challenges of late onset SOS as proposed by the EBMT diagnostic criteria.

    Download PDF (312K)
  • Yu Yagi, Yoshiko Atsuta, Koji Kato
    2025 Volume 14 Issue 1 Pages 6-11
    Published: 2025
    Released on J-STAGE: January 15, 2025
    JOURNAL FREE ACCESS

     CD19-directed chimeric antigen receptor (CAR) T-cell therapy represents a paradigm shift in the treatment of relapsed or refractory large B-cell lymphoma. However, the published real-world outcomes in European (EU) cohorts are inferior to those in the United States (US). One factor contributing to this difference is that the average time between leukapheresis and CAR T-cell infusion, known as the vein-to-vein interval, is longer for patients treated in the EU than for those treated in the US. The vein-to-vein interval in Japan is longer than that in the EU and is expected to extend beyond 2022. This presents an important issue that must be immediately addressed. After leukapheresis, some patients do not receive CAR T-cell infusion because of disease progression or complications. Unused apheresis product leads to a loss of treatment opportunities and financial burden. The optimization of hospital bed management, bridging therapies, and infection control is essential for resolving these problems.

    Download PDF (606K)
  • Nobuhiro Tsukada
    2025 Volume 14 Issue 1 Pages 12-20
    Published: 2025
    Released on J-STAGE: January 15, 2025
    JOURNAL FREE ACCESS

     Treatment outcomes of multiple myeloma (MM) have been dramatically improved in past 20 years. IFM/DFCI group reported that triplet induction (bortezomib, lenalidomide, and dexamethasone) followed by up-front high-dose melphalan and autologous stem-cell transplantation (HDM/ASCT) and maintenance therapy lead to median PFS of 50 months. Therefore, up-front HDM/ASCT is considered as standard care even in the era of novel agents. Daratumumab, lenalidomide, and dexamethasone have also been reported to prolong PFS for newly diagnosed transplant-ineligible MM. Quadruplet induction including anti-CD38 antibody will be approved even for transplant-eligible MM in near future. The role of HDM/ASCT for the treatment for AL amyloidosis and POEMS syndrome is also discussed.

    Download PDF (735K)
  • Souichi Shiratori
    2025 Volume 14 Issue 1 Pages 21-29
    Published: 2025
    Released on J-STAGE: January 15, 2025
    JOURNAL FREE ACCESS

     Calcineurin inhibitor+methotrexate has been used as a conventional GVHD prophylaxis for allogeneic haematopoietic stem-cell transplantation (HSCT); however, more intensive GVHD prophylaxis is needed for HSCT with high-risk of GVHD. Antithymocyte globulin (ATG) has been shown the inhibitory effect of GVHD by a series of phase Ⅲ randomized control trials. On the other hand, post-transplant cyclophosphamide (PTCy) has been shown the remarkable GVHD prophylactic effect for HLA haplo-identical transplantation, and now is rapidly expanding for other types of HSCT. Comparative studies of ATG and PTCy is increasing based on retrospective analysis, and interestingly, in which results tend to differ between HLA-matched and HLA-mismatched HSCT. Larger prospective studies are needed to establish the position of both GVHD prophylaxis.

     Recently, novel GVHD prophylaxis based on the new mechanism and concept is developing. Abatacept and vedolizumab have been shown the GVHD prophylactic effect in randomized controlled trials, and both are expected to be introduced into clinical practice in Japan.

    Download PDF (374K)
  • Saburo Tsunoda, Kazuki Kiyohara, Shohei Ikeda, Masumi Sukegawa, Masats ...
    2025 Volume 14 Issue 1 Pages 30-35
    Published: 2025
    Released on J-STAGE: January 15, 2025
    JOURNAL FREE ACCESS

     Autologous peripheral blood stem cell transplantation (auto-PBSCT) was introduced into the Aizu region of Fukushima Prefecture, with 18 cases performed between 2013 and 2023. The median age of the patients was 53 years (range: 31 to 68 years), and 10 females and 8 males were included. Among these patients, 10 had malignant lymphoma, 7 had multiple myeloma, and 1 had acute myeloid leukemia. The median observation period was 14.5 months (range: 1 month to 9 years). One patient died from interstitial pneumonia, and 3 patients experienced relapse. The predicted 5-year overall survival (OS) and progression-free survival (PFS) rates were 90.9% (95% CI 50.8-98.7%) and 76.0% (95% CI 40.4-92.0%), respectively. This success was achieved through a collaborative effort involving physicians, nurses, clinical engineers, laboratory technicians, and numerous other staff members. To sustain and further develop this program, it is essential to both retain and recruit skilled personnel, as well as to improve the work environment and related factors. We hope that this review will be helpful for medical facility planning to introduce auto-PBSCT.

    Download PDF (801K)
  • Toshiro Kurokawa
    2025 Volume 14 Issue 1 Pages 36-41
    Published: 2025
    Released on J-STAGE: January 15, 2025
    JOURNAL FREE ACCESS

     Toyama Red Cross Hospital is a medium-sized hospital with 401 beds located in the Hokuriku region in Japan. Department of Hematology was established with two hematologists in April of 2010. We underwent the first hematopoietic stem cell transplantation (HSCT) in October of 2010. Until March of 2024, 271 HSCTs (167 allogeneic and 104 autologous) have been performed for 14 years. They were achieved by the good cooperation of various occupational workers in our hospital. Especially, young doctors showed their excellent abilities in our team. A medical social worker was certified as a hematopoietic cell transplant coordinator (HCTC) of Japanese Society for Transplantation and Cellular Therapy (JSTCT) in December of 2018. Our department finally got certification of Category 1 of JSTCT in April of 2019. A good teamwork has been the most important factor to carry out a lot of HSCTs and the participation of young doctors has given us a great energy. Although it is extremely challenging task to invite residents to hematology department, we should continue to make efforts.

    Download PDF (924K)
  • Hideki Araoka
    2025 Volume 14 Issue 1 Pages 42-47
    Published: 2025
    Released on J-STAGE: January 15, 2025
    JOURNAL FREE ACCESS

     Antimicrobial resistance is a major problem at the global level. The epidemiology of antimicrobial-resistant Gram-negative pathogens is known to vary by country and region. The risk of antimicrobial-resistant Gram-negative infections is increased in patients with hematological malignancies, especially in hematopoietic stem cell transplant recipients, due to risk factors such as neutropenia and/or prophylactic fluoroquinolone administration. Therefore, it is important to identify the infectious organ, causative pathogens, and drug susceptibility in patients with suspected active infections. In addition, we should use appropriate antimicrobial agents to improve patient prognosis. This review summarizes the current status of antimicrobial-resistant Gram-negative pathogens, the development of new antimicrobial agents, and therapeutic strategies for antimicrobial-resistant Gram-negative infections.

    Download PDF (401K)
feedback
Top